Diabetes care company embecta launched its new brand recently. The comprehensive rebranding effort received strong professional support from the biopharmaceutical subsidiary of the Waigaoqiao Group.
For embecta, which was spun off from the diabetes care division of BD and now operates independently, this represents not just a brand refresh but a significant milestone marking a new phase of development for its China business.
In the medical industry, a brand refresh is never merely a name change. For a multinational corporation already deeply embedded in the Chinese market with products widely used across hospitals, the real determinant of success in this new phase is the complex restructuring process behind the scenes.
Waigaoqiao has witnessed and actively participated in this invisible yet crucial journey. Waigaoqiao Biopharma provided end to end support in areas such as innovative pilot policies, operational compliance consulting, government affairs, and market access, helping the company seamlessly connect critical links.
This effort reflects the deepening service capabilities of Waigaoqiao’s industrial ecosystem. Building on the group’s existing service framework, Waigaoqiao Biopharma has further developed specialized capabilities in innovation access, pathway design, resource coordination, and implementation support, establishing a new foundation and incremental value for serving multinational healthcare companies.
In the future, Waigaoqiao Biopharma will continue to provide strategic planning and implementation services for innovation access to multinational healthcare companies, helping more high quality enterprises achieve stable and deeper growth in the Chinese market.
